Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Observational × exemestane × Endocrine × Clear all

Status

Sponsor Class

Study Type

Interventional 2 Observational 1

Sponsor

Cancer Type

Breast 18 Other 2 Endocrine 1

Conditions

Neoplasm Metastasis 1 Multiple Endocrine Neoplasia Type 1 1

Interventions

Surveys and Questionnaires 7 Blood Specimen Collection 7 lutetium Lu 177 dotatate 6 Surgical Procedures, Operative 6 Magnetic Resonance Spectroscopy 5 Adrenalectomy 5 Observation 4 Transurethral Resection of Prostate 3 Thyroidectomy 3 Lymph Node Excision 3 Data Collection 3 telotristat ethyl 2 Somatostatin 2 Radiofrequency Ablation 2 Everolimus 2 Biopsy 2 surufatinib 1 somapacitan 1 methyl hydroxyethyl cellulose 1 lanreotide 1 gallium Ga 68 dotatate 1 exemestane 1 delta 24-sterol reductase 1 copper dotatate CU-64 1 Whole Body Imaging 1 Walking 1 Tissue Banks 1 Tamoxifen 1 Sunitinib 1 Staining and Labeling 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02753686 2023-02-15

Treat ER+ight

Novartis

Neoplasm Metastasis, Multiple Endocrine Neoplasia Type 1

Data powered by HemOnc (CC BY 4.0) Colophon ⚡